You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康諾亞-B(2162.HK)首日上市高開46.34%
格隆匯 07-08 09:24
格隆匯7月8日丨康諾亞-B今日首日上市高開46.34%報78港元,市值211億港元。公司IPO定價53.30港元,公開發售獲429.97倍認購。康諾亞生物是一家專注自體免疫及腫瘤治療領域的創新生物醫藥公司,目前已建立擁有9種可進入實驗性新藥申請及後期階段的候選藥物產品線。其中,核心產品CM310是一種針對白介素4受體α亞基(IL-4Rα)的高效抗性抗體,可用於治療中重度特應性皮炎(AD)、中重度嗜酸性哮喘和慢性鼻竇炎伴鼻息肉(CRSwNP)及潛在慢性阻塞性肺病(COPD)。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account